Skip to NavigationSkip to content

Top Ten most popular articles on Pharmafile.com this week

Published on 17/08/18 at 11:12am

This week’s pharmaceutical headlines were dominated by legal spats as the state of New York sued OxyContin drug maker Purdue Pharma and a Chicago judge overturned a $140 million verdict against AbbVie while Indian biotech owner Nitin Sandesara was detained in Dubai.

However the biggest story of the week covered Allergan’s appointment of Pfizer CMO Charles Hugh-Jones as their new Senior Vice President and Chief Medical Officer. Meanwhile Gilead’s CMO announced his departure, as the company appointed two new executives.

For all the latest pharmaceutical news and updates, check out this week's ten most popular articles on Pharmafile.com now!

10. NICE rejects Biogen's spinal muscular dystrophy drug Spinraza after long delay

UK watchdog NICE has rejected Biogen’s spinal muscular dystrophy drug Spinraza (nusinersen) over cost concerns, denying patients the only available treatment for the condition.

9. Indian biotech owner detained in Dubai over £550m fraud allegations­­­

Indian businessman Nitin Sandesara, the owner of the Gujarat-based pharmaceutical company Sterling Biotech has been detained in Dubai in relation to INR 50 billion (£550 million) fraud allegations.

8. Astellas acquires gene therapy group Quethera in £85 million deal

The Japanese company Astellas Pharma has acquired British gene therapy group Quethera in a deal worth up to £85 million.

7. New York sues Purdue Pharma over opioid crisis

New York State have sued OxyContin drug maker Purdue Pharma over allegations surrounding widespread fraud and deception in the marketing of opioids.

6. "Triple pill" blood pressure combo proves more effective, safe than standard care

A “triple pill” combining three established and effective drugs at low dosage levels could prove much more effective in treating high blood pressure than any of its constituent elements alone, according to research conducted by the George Institute for Global Health.

5. Gilead CMO announces departure alongside two new exec appointments

Gilead has announced that its Chief Medical Officer is to vacate the role after just five months and leave the company in order to “pursue another opportunity”.

4. ABPI Chief warns of Brexit impact on EU

The head of the Association of the British Pharmaceutical Industry (ABPI) has warned that European governments have failed to recognise the impact a no-deal Brexit would have on medical supply chains between Europe and the UK.

3. NHS scraps restriction on availability of J&J's Imbruvica in leukaemia patients

The NHS has dropped a controversial restriction preventing leukaemia patients from accessing Johnson & Johnson’s tyrosine kinase inhibitor Imbruvica (ibrutinib), expanding its use to cover treatment-naïve patients with chronic lymphoblastic forms of the condition (CLL).

2. Chicago Judge overturns $140 million AbbVie AndroGel verdict

A US Judge has overturned a $140.1 million verdict against the New York-listed AbbVie Inc.

1. Pfizer CMO Charles Hugh-Jones set to join Allergan in return to New Jersey

Allergan has appointed Pfizer CMO Charles Hugh-Jones as their new Senior Vice President and Chief Medical Officer, as the board certified physician makes a return to New Jersey.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches